Format

Send to

Choose Destination
Cancer Lett. 2005 Sep 8;227(1):9-23. Epub 2004 Dec 15.

Antitumor activity of HER-2 inhibitors.

Author information

1
Wyeth Research, 401 N. Middletown Road, Pearl River, NY 10965, USA. rabinds@wyeth.com

Abstract

Activation of intracellular mitogenic signal transduction pathways driven by the ErbB family of receptor tyrosine kinases has been implicated in a variety of cancers. Amongst these, the tumorigenic roles of the Epidermal Growth Factor receptor (EGFR) and HER-2 have been most extensively studied. Therapeutic antibodies and small molecule kinase inhibitors targeting EGFR have recently received regulatory agency approval for the treatment of colon and lung cancer, respectively. In this review, I briefly describe these agents and their potential use in inhibiting the growth of tumors that overexpress HER-2. I also discuss other therapeutics currently available or being developed specifically to target HER-2 dependent tumors.

PMID:
16051028
DOI:
10.1016/j.canlet.2004.11.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center